This program offers 1 MCLE credit. You must register in advance to participate.

When is a diagnostic method an abstract idea? Can you still patent isolated natural products? Are methods of treatment routine and conventional? What are the limits to patent eligibility when a machine learns a clinical protocol? This webinar will explore these questions, address recent case law and updates to the USPTO Guidelines, and leave you with some practice tips.

Moderator: Sanjesh Sharma

Karen Canady is a founding partner of Canady + Lortz LLP, where her practice focuses on biotechnology patent preparation and prosecution, client counseling, patent clearances and opinion work, and due diligence.

Some examples of her work include developing and prosecuting a patent portfolio on lentiviral gene delivery, which was sold for $12 million, and evaluating a patent portfolio of antisense molecules to help a client close a licensing deal for an upfront fee of $45 million with potential for over $230 million in milestone payments.

Dr. Canady has a JD from University of Washington School of Law, a PhD in Behavioral Neuroscience from University of Washington, and a Bachelor of Science degree from Pacific University. While a law student, she worked part-time at the University of Washington technology transfer office, then at a Seattle intellectual property firm.

She spent her first year after law school as a trainee with a European patent firm in Munich. After spending the next two-and-a-half years at a mid-size intellectual property firm, she founded the biotechnology practice group at a small Los Angeles boutique firm, and in 2006, merged her practice with Origin Law to form Canady + Lortz LLP.